Home > Boards > US Listed > Biotechs > Actinium Pharmaceuticals, Inc. (ATNM)

for me, ATNM is not:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
timberwolf7 Member Profile
 
Followed By 3
Posts 258
Boards Moderated 0
Alias Born 02/06/19
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2021 5:01:48 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/31/2021 5:01:49 PM
Actinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapy Seeking Alpha - 3/24/2021 8:10:31 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 4:45:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/20/2020 5:01:19 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/28/2020 4:18:50 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2020 4:16:20 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/23/2020 5:02:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/7/2020 5:02:07 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/7/2020 5:01:10 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/17/2020 6:21:29 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:23:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:22:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:19:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:18:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/14/2020 5:07:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:05:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:05:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:04:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2020 5:03:59 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/12/2020 6:01:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2020 4:32:08 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 5:11:05 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 7/13/2020 5:10:51 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/30/2020 6:32:21 AM
timberwolf7   Wednesday, 12/09/20 09:28:59 AM
Re: GoodGuyBill post# 2530
Post # of 2570 
for me, ATNM is not:

-a sexy development that wall street can super hype up like a diabetes, cancer or Alzheimer development. So its not one I have seen get a lot of attention since I first got into it in 2016 (note, till the r/split, I was trading runs for gains if I could time it, and then reload. So made something while it was essentially running flat)

-its not even a NEEDED product in that its filling a 'hole' in the health care system. To me, its a BENEFICIAL development, its making something taking place more effective. So its not going to get a lot of attention from the aspect that 'look at how big its market' will be either.

Concluding this way back in 2016, my goal from buying a lot at an initial cost basis of 25 cents, was to see it get to $3/sh on FDA approval. Now that doesn't sound like a lot, but for the share count I was planning on having, $3 was very achievable as most drug approvals see their share prices get caught up in a momentum run with $5-8 at least achieved (before folks start to question things like sales, revenues, etc)

Now? with only 11-14 Million shares outstanding? That $3 target would now be $90, cut that into a 1/3rd to be more 'reasonable' market cap, and its still around a 200% return from this price level.. I can live with ATNM being a little quiet while it finishes up. Especially since I am selling covered calls while I wait.

So to close, is there something nefarious going on? Don't know, but again, I am using Dec 2021 for the completion date of the PH 3 and because of some chatter from management themselves, kind of wondering if there might be a surprise forthcoming (smile).. (as I got on CRMD (Ph 3 halted at the interim/halfway point because of the results) which has an FDA approval date of 28 Feb, current share price of $8.5, expectations of $20-25 based on potential sales, $30-40 if they get approval to expand their market to another sector that shouldnt' require any additional trials because of the identical usage the product would apply to)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences